Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01545947 |
Recruitment Status :
Completed
First Posted : March 7, 2012
Last Update Posted : November 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung Non-Small Cell Lung Cancer | Drug: CC-223, erlotinib Drug: CC-223, oral azacitidine | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 76 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF THE MTOR KINASE INHIBITOR CC-223 IN COMBINATION WITH ERLOTINIB OR ORAL AZACITIDINE IN ADVANCED NON-SMALL CELL LUNG CANCER |
Actual Study Start Date : | May 1, 2012 |
Actual Primary Completion Date : | December 11, 2014 |
Actual Study Completion Date : | December 11, 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: CC-223/erlotinib concurrent
Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
|
Drug: CC-223, erlotinib
Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study. Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy |
Experimental: CC-223/oral azacitidine concurrent
Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
|
Drug: CC-223, oral azacitidine
Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study. Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy |
Experimental: CC-223/oral azacitidine sequential
Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
|
Drug: CC-223, oral azacitidine
Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study. Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy |
- Adverse events [ Time Frame: Up to 24 months ]Number of participants with adverse events
- MTD [ Time Frame: Up to 24 months ]Maximum tolerated dose (MTD)
- PK-Cmax [ Time Frame: Up to 15 months ]Pk-Maximum observed concentration in plasma (Cmax)
- PK-AUC [ Time Frame: Up to 15 months ]Area under the plasma concentration-time curve (AUC)
- PK-Tmax [ Time Frame: Up to 15 months ]PK-Time to maximum concentration (Tmax)
- PK-T1/2 [ Time Frame: Up to 15 months ]PK-Terminal half-life (T1/2)
- PK-CL/F [ Time Frame: Up to 15 months ]PK-Apparent total body clearance (CL/F)
- PK-Vz/F [ Time Frame: Up to 15 months ]PK-Apparent volume of distribution (Vz/F)
- mTORC1 and mTORC2 pathway biomarkers [ Time Frame: Up to 15 months. ]The effect of treatment on mTORC1 and mTORC2 pathway biomarkers in blood and tumor
- CC-223 metabolite, M1 [ Time Frame: Up to 9 months ]CC-223 metabolite, M1, will be characterized
- Tumor Response Rate [ Time Frame: Up to 24 months ]Tumor Response Rate using RECIST 1.1 (Eisenhauer, 2009)
- Number of participants surviving without tumor progression [ Time Frame: Up to 24 months ]Number of participants surviving without tumor progression

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Men and women, 18 years or older, with histologically or cytologically-confirmed, Stage IIIB/IV Non-Small Cell Lung Cancer with tumor progression following at least one prior treatment regimen (either chemotherapy or an Epidermal Growth Factor Receptor inhibitor) for advanced disease. There is no restriction on the number of prior treatment regimens allowed.
- Eastern Cooperative Oncology Group Performance Score of 0 to 1.
- Adequate organ function.
- Adequate contraception (if appropriate).
- Consent to retrieve archival tumor tissue.
- Consent to repeated tumor biopsy (dose expansion phase).
Exclusion Criteria:
- Prior systemic cancer-directed treatments or investigational drugs within 4 weeks or 5 half lives, whichever is shorter except erlotinib which may be continued with intervention in subjects allocated in Arm A.
- Symptomatic central nervous system metastases.
- Acute or chronic pancreatitis.
- Persistent diarrhea or malabsorption > Grade 2, despite medical management.
- Impaired cardiac function or significant cardiac disease.
- Diabetes on active treatment, fasting blood glucose > 126 mg/dL, HbA1c > 6.5%.
- Known Human Immunodeficiency Virus, chronic hepatitis B or C infection.
- Prior treatment with an investigational dual TORC1/TORC2, PI3K, or Akt inhibitor. Prior treatment with rapalogs is allowed.
- Major surgery < 2 weeks prior to starting study drugs. No specific wash out is required for radiotherapy. Subjects must have recovered from any effects of recent therapy that might confound the safety evaluation of study drug.
- Pregnant or breastfeeding, inadequate contraception.
- History of concurrent second malignancies requiring ongoing systemic treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01545947
United States, California | |
Cedars Sinai Medical Center, Inflammatory Bowel Disease Center | |
Los Angeles, California, United States, 90048 | |
University of California, San Francisco | |
San Francisco, California, United States, 9411 | |
United States, New York | |
NYU School of Medicine | |
New York, New York, United States, 10016 | |
United States, South Carolina | |
Cancer Center of the Carolinas | |
Greenville, South Carolina, United States, 29605 | |
United States, Tennessee | |
Henry-Joyce Cancer Clinic | |
Nashville, Tennessee, United States, 37232-5505 | |
United States, Texas | |
Mary Crowley Cancer Research Centers - Medical City | |
Dallas, Texas, United States, 75201 | |
The University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
Spain | |
Vall d´Hebron University Hospital | |
Barcelona, Spain, 08035 | |
Hospital Virgen del Rocio Servicio de Hematologia | |
Sevilla, Spain, 41013 |
Study Director: | Kristen Hege, MD | Celgene Corporation |
Responsible Party: | Celgene |
ClinicalTrials.gov Identifier: | NCT01545947 |
Other Study ID Numbers: |
CC-223-NSCL-001 2011-005290-23 ( EudraCT Number ) |
First Posted: | March 7, 2012 Key Record Dates |
Last Update Posted: | November 12, 2019 |
Last Verified: | November 2019 |
Neoplasms Pulmonary Lung Cancer Cancer of the Lung |
Stage IIIB Non-Small Cell Lung Cancer IV Non-Small Cell Lung Cancer Non-Small Cell Lung Cancer |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic |
Bronchial Neoplasms Erlotinib Hydrochloride Azacitidine Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antimetabolites |